Form 4: Penumbra CFO's Equity Moves Amidst Boston Scientific Merger Talk

Penumbra's CFO, Maggie Yuen, reported recent RSU grants and tax-related share dispositions, with accelerated vesting tied to a potential merger with Boston Scientific.

Summary

• Maggie Yuen, Chief Financial Officer of Penumbra Inc. (PEN), reported several equity transactions.
• On February 13, 2026, Yuen was granted 2,630 restricted stock units (RSUs) under the Issuer's Amended and Restated 2014 Equity Incentive Plan.
• These RSUs are scheduled to vest 1/4 equally on February 15, 2026, February 15, 2027, February 15, 2028, and February 15, 2029, contingent on continued service.
• On February 15, 2026, 481 shares of common stock were disposed of at a price of $339.3 per share to satisfy tax withholding obligations related to RSU vesting.
• On February 17, 2026, Yuen received an additional grant of 2,630 RSUs under the same plan, with vesting scheduled annually starting February 15, 2027.
• A significant condition for both RSU grants is that any unvested RSUs will fully vest upon the 'Closing' of an Agreement and Plan of Merger, dated January 14, 2026, among Penumbra Inc., Boston Scientific Corporation, and Pinehurst Merger Sub, Inc., subject to continued service.
• Following these transactions, Maggie Yuen beneficially owns 20,785 shares of Penumbra Inc. common stock, a portion of which remains subject to vesting.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive. The RSU grants align management incentives, and the explicit mention of a merger agreement with Boston Scientific Corporation is a significant, potentially value-enhancing event for shareholders, despite the routine tax-related share disposition.

Positives

• The Chief Financial Officer received grants of 5,260 restricted stock units (RSUs), aligning management's interests with shareholder value.
• The RSU grants include a provision for accelerated vesting upon the closing of a potential merger with Boston Scientific Corporation, indicating a significant strategic development for Penumbra.

Negatives

• 481 shares of common stock were disposed of to cover tax withholding obligations, resulting in a reduction of direct beneficial ownership.

Risks

• The accelerated vesting of RSUs is contingent on the 'Closing' of the merger with Boston Scientific Corporation, implying that the merger is not yet finalized and could potentially not occur.
• Continued service by the Reporting Person is required for both scheduled and accelerated vesting, posing a risk to the full realization of the RSU value if employment ceases.

Future Outlook

The filing indicates a potential future merger between Penumbra Inc. and Boston Scientific Corporation, as evidenced by the accelerated vesting clause for restricted stock units tied to the 'Closing' of an Agreement and Plan of Merger dated January 14, 2026. This suggests a significant strategic event is anticipated.

Industry Context

StockSavvy.ai notes that insider equity transactions, particularly RSU grants, are common mechanisms for aligning management incentives with company performance. The explicit mention of a merger agreement with Boston Scientific Corporation is a critical development, signaling potential consolidation within the medical device industry and a strategic move for Penumbra to potentially expand its market reach or product portfolio through acquisition by a larger player.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact from the strategic merger with Boston Scientific Corporation, which could lead to increased value or market position. Management's equity alignment also benefits shareholders.
• Employees (specifically Maggie Yuen): Direct impact through RSU grants and potential accelerated vesting, increasing personal wealth and retention incentives.
• Boston Scientific Corporation: The filing confirms their involvement in a merger agreement with Penumbra Inc., indicating a strategic expansion or acquisition.

Next Steps

• Scheduled vesting of restricted stock units on various dates through February 15, 2029.
• Potential 'Closing' of the Agreement and Plan of Merger with Boston Scientific Corporation, which would trigger accelerated vesting of unvested RSUs.

Key Dates

Keywords

Penumbra, PEN, Maggie Yuen, CFO, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Transaction, Form 4, Boston Scientific, Merger, Acquisition